• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research

Association Between Aromatase Inhibitors and Myocardial Infarction Morbidity in Women With Breast Cancer: A Meta-Analysis of Observational Studies
CONCLUSION: Based on real-world data, AIs may be a safe treatment route for patients with estrogen receptor-positive breast cancer and those with a history of CVD. AIs caused a major decrease in MI in patients without CVD history. However, more in-depth investigations are needed to explore the association between AI use and the incidence of MI in the treatment of estrogen receptor-positive breast cancer.PMID:36346929 | DOI:10.1177/10732748221132512
Source: Cancer Control - November 8, 2022 Category: Cancer & Oncology Authors: Jing-Chao Sun Ze-Fan Sun Chao-Jie He Chang-Lin Zhai Gang Qian Source Type: research

Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research

Risk of mortality and other adverse outcomes from myocardial infarction in cancer survivors: a meta-analysis
ConclusionThis meta-analysis shows that cancer increases the risk of all-cause mortality, recurrent MI, and major bleeding in MI patients but is not associated with the risk of cardiovascular death. Therefore, comprehensive multidisciplinary management and monitoring of potential future adverse events in MI patients with cancer are needed.Systematic review registrationThe meta-analysis was registered in the International Register of Prospective Systematic Reviews (NO. CRD42022332775).
Source: International Journal of Clinical Oncology - November 28, 2022 Category: Cancer & Oncology Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - December 31, 2022 Category: Cancer & Oncology Source Type: research

Pages: 1  2  3  4  5  6  7  8